Kangle Guardian’s application for marketing authorization of trivalent HPV vaccine has been accepted
April 25, 2025
Source: drugdu
48
On the evening of April 23, Kangle Guardian (833575) issued an announcement stating that the company's holding subsidiary Kangle Guardian (Kunming) Biotechnology Co., Ltd. received the "Acceptance Notice" issued by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration. The company's independently developed recombinant trivalent human papillomavirus (16/18/58) vaccine (Escherichia coli) (hereinafter referred to as "trivalent HPV vaccine") has been accepted by CDE for marketing authorization.
Kangle Guardian said that the trivalent HPV vaccine is the company's first vaccine to submit a marketing authorization application. If it is successfully approved for listing, it will become the company's first commercial product.
https://finance.eastmoney.com/a/202504233386109657.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Stem cell therapy leads the transformation of Japanese medicine April 30, 2025
- Ruizhi Pharmaceutical’s loss in 2024 was reduced to 226 million yuan, and its operating income fell by 14.8% April 30, 2025
- Renmin Pharmaceutical’s revenue in 2024 is 25.435 billion yuan, and the controlling shareholder’s reorganization is about to be implemented April 30, 2025
- Tasly’s pharmaceutical industry revenue grew steadily in the first quarter April 30, 2025
- Hualan Vaccine’s net profit attributable to the parent company in the first quarter was 32.78 million yuan, a year-on-year decrease of 15.1% April 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
